Lessons From the ARCHER Trial - Summary - MDSpire

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

  • By

  • Margaret Chang, MD

  • July 15, 2026

  • 2 min

Share

Objective:

To discuss findings from the phase 2 ARCHER trial of vonaprument and their implications for the ongoing phase 3 ARCHER II study.

Approach:
  • Trial Overview: The ARCHER trial evaluated vonaprument, a nonpegylated Fab targeting C1q, in patients with geographic atrophy (GA).
  • Risk Factor Analysis: The trial identified baseline risk factors for 15-letter vision loss, focusing on patients with compromised vision and subfoveal lesions.
Key Findings:
  • Patients with vision between 20/40 and 20/100 were at highest risk for 15-letter loss.
  • Subfoveal lesions increased the risk of 15-letter loss compared to nonsubfoveal lesions.
Interpretation:

The findings from the ARCHER trial informed the design of the phase 3 ARCHER II study, aiming to improve outcomes for patients with GA.

Conclusion:

The phase 3 ARCHER II study is expected to read out later this year.

Original Source(s)

Lessons From the ARCHER Trial

  • by Margaret Chang, MD

  • July 15, 2026

Related Content

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.

The New Rules of Retina Drug Development

In a panel at the Retina Innovation Summit in Montreal, regulatory experts, drug developers, academic advisors, and investors discussed how evolving FDA guidance is reshaping the path from clinical trials to approval.

Ocular Toxoplasmosis Review

Sleep, stress, and pregnancy emerge as potential drivers of ocular toxoplasmosis recurrence in recent retrospective study

  • July 15, 2026

  • 4 min